Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
When Bug got home from school one winter afternoon in late 2024, his mother was on...
More than 3.1 million bottles of eye drops sold at major retailers, including Walgreens and CVS,...
Donald Trump has selected Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC),...
The Supreme Court sided with a Christian counselor on Tuesday in her free speech challenge to...
